Multicenter Clinical Trial to Evaluate the Efficacy of a Preventive Strategy Against CMV Infection in Heart Transplant Patients, Based on the Specific T Cells Response — ELISPOT-TC

CMV Infection Clinical Trial

Official title:
Phase IV Clinical Trial, Open, Randomized, Controlled and Multicentric, With Two Parallel Groups, to Assess the Efficacy of a Preventive Strategy Against Cytomegalovirus Infection in Heart Transplant Patients, Based on the Specific Basal T Cell Response Against Cytomegalovirus: ELISPOT-TC

Status Recruiting

Clinical Trial Summary

This study evaluates the efficacy and safety of an individualized preventive strategy against CMV infection in CMV seropositive heart transplant patients based on the specific basal response of the lymphocytes againts CMV (ELISPOT Interferon-γ assay). In two thirds of the patients a preventive strategy will be carried out based on the result of the ELISPOT IFN-γ assay and in one third of the patients the standard of care strategy will be carried out (universal prophylaxis).

Clinical Trial Description

Background: The prevention of Cytomegalovirus (CMV) infection in cardiac transplant patients is currently based exclusively on the performance of the serotypes of the receptor and the donor. Despite prophylactic treatment with valganciclovir or preemptive therapy through serial monitoring of blood viral copies, the rate of infection or CMV disease remains high and has a negative clinical impact. The evaluation of the specific T lymphocytes cellular immune response against 2 CMV antigens prior to kidney transplantaction, using the ELISPOT IFN-γ assay discriminates in a better way which patients will develop CMV infection. Objetives: To compare the cumulative incidence of CMV infection during the first year post-heart transplant amongst CMV seropositive recipients in 12 national centers, where the prophylactic strategy regarding CMV infection will be guided by the ELISPOT IFN-γ assay or not (control). Main variable: number of patients who have CMV infection in the first year post-trasplant (HT). Hyphotesis: A preventive strategy against CMV infection in CMV seropositive heart transplant patients, based on the specific basal response of the T lymphocytes against CMV, ELISPOT IFN-γ assay, is effective, safe and not inferior than the control group in terms of infection CMV rates. Design: The investigators propose a phase IV clinical trial (with authorized treatment), randomized (2:1), controlled, open label and multicentric, with two parallel groups (Experimental group: preventive strategy based on the ELISPOT IFN-γ result: If patients are stratified as high risk they will receive prophylaxis with valgancyclovir for 3 months and if they are stratified as low risk they will be treated with preemptive therapy guided by CMV polymerase chain reaction analysis; Control group: Standard of care, universal prophylaxis with valgancyclovir for 3 months). Follow-up: 1 year. Duration of the trial: 3 years. Sample size: 188 patients. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT04278547
Study type	Interventional
Source	Hospital Universitari de Bellvitge
Contact	Jose González Costello
Phone	+0034 932607686
Email	jgonzalez@bellvitgehospital.cat
Status	Recruiting
Phase	Phase 4
Start date	June 12, 2020
Completion date	March 25, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT03067155` - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation.	Phase 2
Completed	`NCT02324244` - CMV Intensive Care Units	N/A
Enrolling by invitation	`NCT06263218` - Real-world CMV Outcomes Among Kidney Transplant Recipients in Brazil
Recruiting	`NCT04934527` - Association of T Gamma Delta-CD16+ Cells and Anti-CMV Immunoglobulins in the Prevention of CMV Infection	Phase 2
Not yet recruiting	`NCT06075927` - Multivirus-specific T Cells in the Treatment of Refractory CMV and/or EBV Infection After Allo-HSCT	Phase 1/Phase 2
Not yet recruiting	`NCT06341686` - Evaluation of the Prophylactic Use of Letermovir in Kidney Transplant Recipients at Risk of Cytomegalovirus Infection	Phase 3
Recruiting	`NCT02136797` - Trial of Third Party Donor Derived CMVpp65 Specific T-cells for The Treatment of CMV Infection or Persistent CMV Viremia After Allogeneic Hematopoietic Stem Cell Transplantation	Phase 2
Terminated	`NCT02843880` - Prediction of Cytomegalovirus (CMV) Reactivation in Intensive Care Unit (ICU) by Immunological Study	N/A
Recruiting	`NCT06021210` - Letermovir for the Prevention of CMV Infection in HSCT Recipients Based on the Outcome of mNGS	Phase 2
Active, not recruiting	`NCT01633476` - CMV Modulation of the Immune System in ANCA-associated Vasculitis	Phase 2
Suspended	`NCT02988258` - Study of Adoptive Immunotherapy With Donor-derived CMV-specific T Cells for Recipients of Allo-HSCT	Phase 1
Recruiting	`NCT04017962` - A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection	Phase 2
Recruiting	`NCT03159364` - Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections	Phase 1/Phase 2
Recruiting	`NCT05089838` - CMV-TCR-T Cells for Refractory CMV Infection After HSCT	Phase 1
Enrolling by invitation	`NCT05656599` - Immune Reconstitution to CMV After HSCT: Impact of Clinical Factors and Therapy Strategies
Completed	`NCT02985775` - Preemptive Therapy With CMV-specific T Cells Infusion to Prevent Refractory CMV Infection Post Transplantation	Phase 1/Phase 2
Recruiting	`NCT02083731` - MSC for Treatment of CMV Infection	Phase 2
Recruiting	`NCT02779439` - Partially HLA-matched Third Party Antigen Specific T-cells for Infection Post-stem Cell or Solid Organ Transplantation	Phase 1
Recruiting	`NCT03798301` - Treatment of Cytomegalovirus (CMV) Infections With Viral-Specific T Cells	Phase 1
Completed	`NCT02550639` - Prospective, Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection Based on Baseline hCMV Specific T-cell Response in Kidney Transplant	Phase 4